These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28977890)

  • 1. Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy.
    Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Kinoshita T; Yamada K; Sasada T; Akiba J; Hoshino T
    Oncotarget; 2017 Sep; 8(37):61618-61625. PubMed ID: 28977890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death ligand 1 expression and CD8
    Zhou J; Gong Z; Jia Q; Wu Y; Yang ZZ; Zhu B
    Biochem Biophys Res Commun; 2018 Apr; 498(4):751-757. PubMed ID: 29526752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
    Ishii H; Azuma K; Kawahara A; Yamada K; Imamura Y; Tokito T; Kinoshita T; Kage M; Hoshino T
    J Thorac Oncol; 2015 Mar; 10(3):426-30. PubMed ID: 25384063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma.
    Ono T; Azuma K; Kawahara A; Sasada T; Hattori S; Sato F; Shin B; Chitose SI; Akiba J; Hirohito U
    Oncotarget; 2017 Nov; 8(54):92699-92714. PubMed ID: 29190949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers.
    Kim KJ; Yang HK; Kim WH; Kang GH
    Oncotarget; 2017 Aug; 8(35):58887-58902. PubMed ID: 28938605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer.
    Ju X; Shen R; Huang P; Zhai J; Qian X; Wang Q; Chen M
    Oncotarget; 2017 Nov; 8(59):99372-99381. PubMed ID: 29245908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression.
    Lin Z; Gu J; Cui X; Huang L; Li S; Feng J; Liu B; Zhou Y
    J Cancer; 2019; 10(1):211-222. PubMed ID: 30662542
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer.
    Lin G; Fan X; Zhu W; Huang C; Zhuang W; Xu H; Lin X; Hu D; Huang Y; Jiang K; Miao Q; Li C
    Oncotarget; 2017 Oct; 8(48):83986-83994. PubMed ID: 29137398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
    Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
    Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer.
    Cui S; Su X; Dong L; Qian J; Ye L; Zhang T; Fu H; Han H; Huang J; Yao Y; Gu Y; Jiang L
    J Cancer; 2017; 8(19):4075-4082. PubMed ID: 29187883
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer.
    Donnem T; Hald SM; Paulsen EE; Richardsen E; Al-Saad S; Kilvaer TK; Brustugun OT; Helland A; Lund-Iversen M; Poehl M; Olsen KE; Ditzel HJ; Hansen O; Al-Shibli K; Kiselev Y; Sandanger TM; Andersen S; Pezzella F; Bremnes RM; Busund LT
    Clin Cancer Res; 2015 Jun; 21(11):2635-43. PubMed ID: 25680376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells.
    Cui S; Dong L; Qian J; Ye L; Jiang L
    J Cancer; 2018; 9(1):129-134. PubMed ID: 29290777
    [No Abstract]   [Full Text] [Related]  

  • 17. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.
    D'Angelo SP; Shoushtari AN; Agaram NP; Kuk D; Qin LX; Carvajal RD; Dickson MA; Gounder M; Keohan ML; Schwartz GK; Tap WD
    Hum Pathol; 2015 Mar; 46(3):357-65. PubMed ID: 25540867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.